Gilead Sciences (GILD)
(Real Time Quote from BATS)
$83.96 USD
+0.02 (0.02%)
Updated Sep 23, 2024 01:28 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Gilead Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 7,264 | 6,385 | 6,520 | 7,408 | 24,352 |
Receivables | 4,660 | 4,777 | 4,493 | 4,892 | 3,582 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1,787 | 1,507 | 1,618 | 1,683 | 922 |
Other Current Assets | 2,374 | 1,774 | 2,141 | 2,013 | 1,440 |
Total Current Assets | 16,085 | 14,443 | 14,772 | 15,996 | 30,296 |
Net Property & Equipment | 5,317 | 5,475 | 5,121 | 4,967 | 4,502 |
Investments & Advances | 1,163 | 1,245 | 1,309 | 502 | 1,488 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 34,768 | 37,208 | 41,787 | 41,234 | 17,903 |
Deposits & Other Assets | 4,792 | 4,800 | 4,963 | 5,708 | 7,438 |
Total Assets | 62,125 | 63,171 | 67,952 | 68,407 | 61,627 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 550 | 905 | 705 | 844 | 713 |
Current Portion Long-Term Debt | 1,798 | 2,273 | 1,516 | 2,757 | 2,499 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3,802 | 8,059 | 9,389 | 7,796 | 6,547 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5,130 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 11,280 | 11,237 | 11,610 | 11,397 | 9,759 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1,588 | 2,673 | 4,356 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 24,469 | 24,136 | 26,155 | 33,773 | 23,103 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2,039 | 3,916 | 4,767 | 5,016 | 6,115 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 39,376 | 41,962 | 46,888 | 50,186 | 38,977 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 6,500 | 5,550 | 4,661 | 3,880 | 3,051 |
Retained Earnings | 16,304 | 15,687 | 16,324 | 14,381 | 19,388 |
Other Equity | -56 | -29 | 78 | -41 | 210 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 22,749 | 21,209 | 21,064 | 18,221 | 22,650 |
Total Liabilities & Shareholder's Equity | 62,125 | 63,171 | 67,952 | 68,407 | 61,627 |
Total Common Equity | 22,749 | 21,209 | 21,064 | 18,221 | 22,650 |
Shares Outstanding | 1,246.00 | 1,254.20 | 1,254.30 | 1,253.50 | 1,265.10 |
Book Value Per Share | 18.26 | 16.91 | 16.79 | 14.54 | 17.90 |
Fiscal Year End for Gilead Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,772 | 4,718 | 7,264 | 6,864 | 6,667 |
Receivables | 4,663 | 4,669 | 4,660 | 4,790 | 4,229 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2,026 | 1,853 | 1,787 | 1,663 | 1,633 |
Other Current Assets | 2,856 | 2,800 | 2,374 | 2,662 | 1,757 |
Total Current Assets | 12,317 | 14,041 | 16,085 | 15,980 | 14,287 |
Net Property & Equipment | 5,346 | 5,321 | 5,317 | 5,572 | 5,540 |
Investments & Advances | 0 | 0 | 1,163 | 1,156 | 1,334 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 31,146 | 31,742 | 34,768 | 35,466 | 36,064 |
Deposits & Other Assets | 4,770 | 5,188 | 4,792 | 4,200 | 5,113 |
Total Assets | 53,579 | 56,292 | 62,125 | 62,373 | 62,337 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 537 | 622 | 550 | 586 | 622 |
Current Portion Long-Term Debt | 1,810 | 3,667 | 1,798 | 1,793 | 4,037 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3,923 | 4,263 | 3,802 | 3,714 | 3,494 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4,510 | 4,464 | 5,130 | 5,852 | 5,810 |
Total Current Liabilities | 10,781 | 13,015 | 11,280 | 11,945 | 13,964 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 907 | 933 | 1,588 | 1,984 | 2,106 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 21,540 | 22,922 | 24,469 | 24,113 | 22,563 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2,156 | 2,039 | 2,088 | 2,610 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 35,382 | 38,837 | 39,376 | 40,131 | 41,243 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 7,022 | 6,813 | 6,500 | 6,279 | 6,008 |
Retained Earnings | 11,165 | 10,656 | 16,304 | 16,002 | 15,138 |
Other Equity | 9 | -15 | -56 | -41 | -54 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 18,197 | 17,455 | 22,749 | 22,242 | 21,094 |
Total Liabilities & Shareholder's Equity | 53,579 | 56,292 | 62,125 | 62,373 | 62,337 |
Total Common Equity | 18,197 | 17,455 | 22,749 | 22,242 | 21,094 |
Shares Outstanding | 1,245.80 | 1,245.00 | 1,246.00 | 1,246.00 | 1,247.30 |
Book Value Per Share | 14.61 | 14.02 | 18.26 | 17.85 | 16.91 |